#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

IRCCS Humanitas Research Hospital

Verifiedinfo

Italy Via Francesco Nava 31, 20159 Rozzano, Italy

300 trials recruiting
Colitis ulcerative · Crohn's disease · Non-small cell lung cancer
Adults and children

About Specializations

IRCCS Humanitas Research Hospital in Rozzano, Italy specialises in clinical trials of conditions such as Colitis ulcerative, Crohn's disease, Non-small cell lung cancer, Endometrial cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Nephrology

The medical center is at the forefront of nephrology research, focusing on innovative treatments for Idiopathic IgA nephropathy (IgAN). This condition, characterized by the deposition of IgA antibodies in the kidneys, can lead to significant renal impairment.

Targeted therapy based on kidney biopsy findings
Early corticosteroid therapy for active renal lesions
Combination of SGLT2 inhibitors with RASBs for chronic lesions

Through its research, the center aims to refine therapeutic strategies, minimizing the side effects associated with traditional treatments while enhancing patient outcomes. The integration of corticosteroids and SGLT2 inhibitors represents a significant advancement in managing proteinuria in IgAN patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Via Francesco Nava 3120159 RozzanoItaly

Open in maps ↗

Recruiting now: 300 trials
Conditions studied: 193
Partner status: Verified

More sites in Rozzano Italy

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

721 clinical trials

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

Recruiting

InvestigationalNo placebo

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Golimumab
Sponsor:Janssen Cilag International

Contact Research Centre

Colitis ulcerative

Recruiting

Investigational

Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Investigational

Italy

Participants:18–64 years · 65+ years
Sponsor:Eli Lilly & Co.

Contact Research Centre

Colitis ulcerative

Recruiting

Investigational

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:SPY002
Sponsor:Spyre Therapeutics Inc.

Contact Research Centre

Systemic lupus erythematosus

Recruiting

Registered drugNo placebo

Evaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Anifrolumab
Sponsor:AstraZeneca AB

Contact Research Centre

Psoriatic arthropathy

Recruiting

Investigational

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Zasocitinib
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Cardiac failure+1

Recruiting

Investigational

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Italy

Participants:18–64 years · 65+ years
Sponsor:Novo Nordisk A/S

Contact Research Centre

Craniocerebral injury

Recruiting

Investigational

Phase 2a Study of Safety, Tolerability and Efficacy of Intranasal Cenegermin in Adults with Moderate to Severe Subacute Traumatic Brain Injury

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Cenegermin
Sponsor:Dompe' Farmaceutici S.p.A.

Contact Research Centre

Non-small cell lung cancer

Recruiting

InvestigationalNo placebo

A study to evaluate the safety and effectiveness of HLX43 in patients with advanced non-small cell lung cancer

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:HLX43
Sponsor:Shanghai Henlius Biotech Inc.

Contact Research Centre

Eczema nummular

Recruiting

Registered drug

A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Lebrikizumab
Sponsor:Almirall S.A.

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis+1

Recruiting

Investigational

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:BI 456906
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis+1

Recruiting

Investigational

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:BI 456906
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Chronic spontaneous urticaria

Recruiting

Registered drugNo placebo

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Barzolvolimab
Sponsor:Celldex Therapeutics Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.